INSYS Therapeutics, Inc.
INSYS Therapeutics, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2010, the company has made significant strides in developing innovative therapies, particularly in the areas of pain management and substance use disorders. INSYS is renowned for its unique delivery systems, including sublingual formulations that enhance the bioavailability of cannabinoids. Their flagship products, such as Syndros, have positioned the company as a leader in the treatment of chemotherapy-induced nausea and vomiting. With a commitment to advancing patient care, INSYS Therapeutics has achieved notable milestones, including successful FDA approvals and a growing portfolio of proprietary products. The company continues to focus on addressing unmet medical needs, solidifying its market position in the evolving landscape of therapeutics.
DitchCarbon Score
How does INSYS Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
INSYS Therapeutics, Inc.'s score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
INSYS Therapeutics, Inc.'s reported carbon emissions
INSYS Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions data, it is challenging to assess their carbon footprint or climate commitments. However, the absence of reported figures suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy. In the pharmaceutical industry, companies are increasingly recognising the importance of addressing climate change and setting measurable targets to reduce their environmental impact. As such, INSYS Therapeutics may need to establish clear climate commitments and reduction initiatives to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
INSYS Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
